We made separate measurements of angiotensin II (A II) and of its immunoreactire metabolites (2-8 heptapeptide, 3-8 bexapeptide, and 4-8 pentapeptide) in arterial and venous plasma from subjects with widely different plasma levels of the peptides. A II and its three metabolites were extracted from blood, separated by paper chromatography, and measured by radioimmunoassay using an A II antisemm which had a 100% cross-reaction with each metabolite. In contrast to results of previous studies, A II was found to predominate in both arterial (60-100%) and venous (55-100%) blood. The biologically active 2-8 beptapeptide metabolite accounted for only 10% of the activity in arterial plasma. Radioimmunoassay of venous plasma extracts using an A II antisemm which had a low cross-reaction with the 3-8 hexapeptide and the 4-8 pentapeptide confirmed the results obtained using the antisemm which had a 100% cross-reaction with the metabolites. We conclude that radioimmunoassay methods for measuring A II in venous blood may be more accurate and relevant than has previously been recognized. The small difference between A II concentrations in arterial and venous plasma suggests further that there may be significant conversion of angiotensin I (A I) to A II in the limb vasculature.
THE PRESSOR octapeptide, angiotensin II (A II), coexists in blood with its major metabolites, the C-terminal 2-8 heptapeptide, 3-8 hexapeptide, and 4-8 pentapeptide. Compared to A II, the heptapeptide has only weak pressor activity in the rat, whereas the remaining metabolites have none. 1 ' * In contrast, the heptapeptide is equally as potent as A II in stimulating aldosterone secretion in the sheep' and in the conscious rat,'1 and more potent as a stimulus to aldosterone biosynthesis in vitro using rabbit capsular adrenal tissue. 5 The aldosterone-stimulating properties of the remaining metabolites are weak.*-* Antisera raised against A II usually cross-react with the C-terminal heptapeptide and hexapeptide metabolites'-' and sometimes also with the pentapeptide metabolite.' Radioimmunoassays of A II thus measure not only A II but also these immunoreactive metabolites. A II can be separated from metabolites by chromatography of blood extracts before immunoassay. Cain et al.*"" used this approach and found that A II comprised 85% of the immunoreactive material in human arterial blood, but only 28% of that in venous blood. In venous blood, they found the major immunoreactive substance to be the hexapeptide, although the concentrations of hepta-and pentapeptides were not determined.
Our present paper describes a method for determining the relative proportions of A II and the three major peptide metabolites in arterial and venous blood, and the results obtained in a group of subjects with a wide range of circulating levels of renin and A II. Further, because the analogue of A II, l-Asp(NH,)-5-Val-angiotensin II, often used in investigations of the renin-angiotensin system, is degraded, in plasma at least, by a different enzyme from that which catalyzes the hydrolysis of natural A II, 1 ' the opportunity was also taken to compare the pattern of A II metabolites in normal venous plasma with that during infusions of this analogue.
Methods

SYNTHETIC PEPTIDES
The following peptides were used: l-Asp-5-Ile-angiotensin I (A I), (Schwarz/Mann); l-Asp-5-lle-angiotensin II (A II) (National Institute for Biological Standards and Control, London); Arg-Val-Tyr-Ile-His-Pro-Phe, Val-Tyr-Ile-His-Pro-Phe, and Tyr-Ile-His-Pro-Phe (Schwarz/Mann); and l-Asp(NH,)-5-Val-angiotensin II (CIBA).
EXTRACTION OF PEPTIDES FROM BLOOD
Method of Diisterdieck and McElwee
The method of extracting A II and its immunoreactive metabolites has been described in detail by Diisterdieck and McElwee." Blood was drawn in samples of 20 ml from the arm and, within 30 seconds after its first appearance, was added in a plastic container to I ml of an aqueous solution of 0.1 M ethylenediaminetetraacetic acid (EDTA) (disodium salt) with 0.05 M o-phenanthroline, a mixture that effectively inhibits blood converting enzyme and angiotensinases. 11 -' 4 After chilling in ice, the mixture was extracted at +5°C and 2,000 g for 20 minutes. The peptides were extracted from a measured volume of plasma by mixing with Dowex AG 5OW-X2, 50-100 mesh (H+ form) and twice eluted from the resin with ammonia-methanol (9:1, vol/ vol). In recovery experiments, venous or arterial blood was collected into syringes containing known quantities of peptides.
Method of Cain et al.
Comparison was made with the extraction method of Cain et al., 1 * in which converting enzyme and angiotensi- VOL. 39, No. 5, NOVEMBER 1976 nases were destroyed by adding whole blood directly to ethanol, the peptides being extracted by Sephadex column chromatography.
PAPER CHROMATOGRAPHY
Residues from Dowex eluates were redissolved in 100 n\ of a mixture of ammonia and methanol (9:1, vol/vol), and 60 fi\ of this were applied as a 1-cm line to the origin of 2.5-cm-wide lanes of a paper chromatogram (Whatman No. 3MM). Marker standards (20 jzg) of l-Asp-5-Ile-angiotensin II or l-Asp(NH 2 )-5-Val-angiotensin II and the immunoreactive metabolites were applied to adjacent lanes. Residues from eluates of Sephadex were treated similarly but dissolved in a mixture of ethanol and 0.1 M acetic acid (7:3, vol/vol 10 ). After equilibration in the solvent system for 4 hours, the chromatograms were developed in either solvent A (n-butanol-aceticacid-water-pyridine, 15:3:12:10, vol/vol, pH 5.2) or solvent B 10 (upper phase, n-butanol-acetic acid-water-ethyl acetate, 10:):5:10, vol/vol, pH 3.1) for 15-16 hours. After the chromatograms were dried in air, the marker lanes were stained by heating at 60°C for 20 minutes after saturation with a mixture of 1% ninhydrin in acetone and 1 % cadmium acetate in 50% aqueous acetic acid (85:15, vol/vol).
Chromatogram lanes bearing the samples were transversely cut at 1-cm intervals and each segment was eluted with 2 ml of ammonia-methanol mixture (see above) in 2-ml syringes for 4 hours. The eluates were then ejected from the syringe into tubes containing 50 fi\ of aqueous human serum albumin solution (1 g/100 ml), the remaining drops in the syringe being recovered by centrifugation (2,000 g, 5 minutes). The solution was evaporated to dryness at 37°C under a stream of cold air.
RADIOIMMUNOASSAY
Radioimmunoassay of A II was performed by the method of DUsterdieck and McElwee. 13 To corroborate the chromatographic findings, A II immunoreactive material (A II IM) in Dowex extracts of normal venous plasma (80 ml) was measured with two antisera that had different affinities for A II metabolites (see Results).
A I was measured by the radioimmunoassay method of Waite." BIOASSAY Bioassay of A II in the pentolinium-treated rat was performed by the method of Peart."
CONTRIBUTION OF A I TO IMMUNOREACTIVE A II CONCENTRATIONS
A I was not separated from A II by paper chromatography, but the A II antiserum used in the radioimmunoassay had a small (0.6%) cross-reaction with A I (see Results). Because chemical inhibitors do not inhibit the renin-renin substrate reaction, A I may be generated in plasma during Dowex extraction. To measure the contribution to apparent A II concentrations made by A I, the following experiments were conducted: (1) Samples (20 ml) of normal venous blood drawn into inhibitor solution were kept at room temperature (20°C) for times varying from 0 to 300 minutes before cooling in an ice bath. Residues from Dowex extraction were divided into two equal portions, one of which was assayed for A I and the other for A II. (2) A I and A II were measured in four extracts of normal venous plasma (40 ml) developed in system A.
CATABOLISM OF A II AND ITS METABOLITES IN BLOOD
Eight picomoles of A II of the hepta-, hexa-, or pentapeptide in 100 fi\ of tromethamine (Tris) buffer, pH 7.5, were added to samples (4 x 50 ml) of venous blood containing heparin (10 U/ml) but not inhibitor, and freshly drawn from a normal subject. A further sample (control) received only Tris buffer. The samples were incubated at 37°C and 10-ml portions, removed at 0, 2, 5, 15, and 30 minutes, were mixed immediately with 0.5 ml of inhibitor solution and cooled in ice. After Dowex extraction and chromatography in system A, the sample values were corrected for the control values.
EFFECT OF DELAY IN ADDING INHIBITOR SOLUTION TO BLOOD
Samples of venous blood (20 ml) were incubated at 20°C for up to 10 minutes without anticoagulant and for up to 60 minutes with heparin (10 U/ml) before adding inhibitor and chilling in ice. One sample was totally hemolyzed with saponin (Zaponin, Coulter Electronics) before incubation for 60 minutes. Samples containing inhibitor from the same subject were incubated as controls. The Dowex extracts were developed in system A.
SUBJECTS
Informed consent was obtained from all subjects, and the protocol of the study was agreed to by the Ethical Supervisory Committee of the Western Infirmary, Glasgow. To obtain information on the distribution of A II and its metabolites over a wide range of circulating renin levels, the following groups were studied. Sample volumes of blood varied from 20 to 40 ml.
Normal Subjects
Forearm venous blood was taken from 22 normal men and women (25-59 years old) who had been recumbent for 5 minutes. The range of plasma concentrations of A II IM measured without paper chromatography by DUsterdieck and McElwee in normal subjects studied in the same way was 5-35 pmol/liter. 13 Comparison was also made of simultaneous forearm venous and arterial blood samples taken after a I-hour period of recumbency from each of five normal subjects between 20 and 73 years in age on an unrestricted diet. In a previous study of eight normal subjects who had been on a fixed normal daily intake of sodium and potassium for 3 days and recumbent overnight, we found a mean concentration of A II IM in brachial arterial plasma of 10.0 pmol/liter (range, 6-17) compared to a mean of 10.4 pmol/liter (range, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] in brachial venous plasma drawn concurrently."
Subjects with Raised Plasma Renin Concentration (PRC)
Forearm venous blood was drawn from: (1) five women between the 30th and 40th weeks of normal pregnancy who had been supine for 1 hour; plasma concentrations of renin and A II 1M are generally high at this stage of pregnancy; 1 ' (2) a 20-year-old man with untreated malignant phase hypertension and a peripheral venous PRC of 179 /iU/ml (normal range, 20-100 jiU/ml, international standard renin"' " ) ; (3) a 25-year-old man with Bartter's syndrome and a PRC of 1,141 M U/ml; and (4) a 54-year-old woman with rheumatic heart disease, being treated with 160 mg of furosemide daily, whose PRC was 110 ^U/ml.
Subjects with Low Plasma Renin Concentration
Arterial blood was drawn from one male (aged 31) and one female (aged 27), from whom both kidneys had been removed 5 weeks and 9 months previously. PRC was 21 and 32 ^U/ml, respectively. Forearm arterial and venous blood was also obtained from an asthmatic patient, on 80 mg of prednisolone a day, whose PRC was 21 ^U/ml.
INFUSION OF l-As^NH.y-S-Val-ANGIOTENSIN II
The pattern of metabolites was examined in venous blood from three normal subjects (ages, 20-30 years) and the patient with Bartter's syndrome during intravenous infusion of l-Asp(NHj)-5-Val-angiotensin II. Samples were taken after 1 hour of an infusion of 5% glucose and after 1 hour of an infusion of l-Asp(NH 2 )-5-Val-angiotensin II in 5% glucose at a rate of 8 pmol/kg per min, the subjects being recumbent throughout. In the patient with Bartter's syndrome, simultaneous venous and arterial samples were obtained.
Results
SEPARATION OF A II FROM IMMUNOREACTIVE METABOLITES BY PAPER CHROMATOGRAPHY
Solvent A separated A II, the 2-8 heptapeptide, and 3-8 hexapeptide (R r values = 0.50, 0.67, and 0.77) but did not separate the 4-8 pentapeptide (R r 0.73) from the 3-8 hexapeptide. Solvent B separated A 11/2-8 heptapeptide (R methyl orange 0.1) from 3-8 hexapeptide/4-8 pentapeptide (R methyl orange 0.6). Neither solvent separated A I from A II.
CROSS-REACTING PROPERTIES OF THE PEPTIDE ANTISERA
The A II antiserum (final dilution, 1:20,000) used for the paper chromatographic studies (antiserum 1) had an equal affinity for A II and l-Asp(NH,)-5-Val-angiotensin II and, in molar terms, a cross-reaction of 0.6% with A I 11 and 100% with the three A II metabolites (Fig. 1) . The other A II antiserum (antiserum 2), used at a final dilution of 1:20,000, had a slightly higher (2.3%) cross-reaction with A I, but a much lower cross-reaction with both the hexapeptide (10%) and pentapeptide (0.6%) (Fig. 2) . The A I antiserum had a cross-reaction with A II of less than 1 x 10-'%."
ACCURACY: RECOVERY OF PEPTIDES FROM BLOOD
A II recoveries were corrected for simultaneously estimated endogenous levels of peptide.
Through the Dowex extraction procedure," recoveries of 2 pmol of the heptapeptide, hexapeptide, and pentapeptide added to venous blood were 86 ± 3% (SD) (n = 4), 80 ± 5% (n = 4), and 82 ± 4% (n = 4), respectively. The recovery of l-Asp-5-Ile-angiotensin II was 83 ± 11% (/»=•= 44), measured by immunoassay, with similar results on bioassay." Through the alcoholic precipitation and Sephadex extraction method, 16 the recovery of 2 pmol of l-Asp-5-Ile-angiotensin II was 72 ± 12% (n = 6).
Through the entire extraction and chromatographic proceedings, there were no differences in recovery of the individual peptides or between the different methods (Table  1) , although recoveries were generally higher when large amounts of peptide were used. The results of blood analysis have therefore not been corrected for recovery. Figure 3 compares the recoveries in two single experiments in which 2 ng* each of A II, heptapeptide, and hexapeptide were added to blood and 50 fi\ of the redissolved Dowex extracts developed in system A or system B.
When an experiment was performed in which 200 ng of each peptide were added to blood and the Dowex extract developed in system A the major peak coincided with the A II region. A minor peak coincided with the heptapeptide region and no pressor activity was found running with the hexa-or pentapeptides. (TABLE 2) A II was the predominant peptide in Dowex extracts of normal venous plasma (78%) and Sephadex extracts of venous blood (96%) developed in system A. Examples are shown in Figure 4 . The concentration of A II was slightly but significantly higher in arterial plasma than in simultaneously drawn venous plasma (paired Mest, P < 0.02). A II was also the predominant peptide in venous samples from pregnant subjects, in subjects infused with l-Asp(NH,)-5-Val-angiotensin II, and in subjects with abnormally high or low PRC. Plasma from both the anephric subjects studied contained immunoreactive material which chromatc- 
COMPARISON OF A II AND IMMUNOREACTIVE FRAGMENTS IN ARTERIAL AND VENOUS BLOOD
II; • • -l-Asp(N H \)-5-Val-antiotensin II; A heptapeptide; • • • -3-8 hexapeplide; D C
tapeptide.
graphed as authentic A II. It was possible to test the pressor activity of immunoreactive A II recovered from a chromatograph developed in solvent system A by analyzing a Dowex extract of a 40-ml sample of venous plasma from a subject with a high PRC. Bioactive angiotensin (10-21 pmol) and 15 pmol of immunoreactive A II (15 pmol) were recovered from the A II position. No other pressor peaks were seen but vasodepressor material chromatographed with an R, value of 0.78. Results obtained with system B were similar to those as with system A, the majority of the A II IM being identified in the A II/heptapeptide position ( Table 3 , Fig. 5 ).
COMPARISON OF IMMUNOREACTIVE A II CONCENTRATIONS OBTAINED USING ANTISERUM 1 AND ANTISERUM 2
Dowex extracts of normal venous blood were assayed for A II concentration using both antisera 1 and 2. The mean concentration of A II IM using antiserum 2 was 18.4 ± 4.4 (SD) pmol/liter (n = 8) and using antiserum 1 it was 18.9 ± 4.8, (n -8). The mean percentage difference between individual extracts was 0.8%. Since antiserum 1 cross-reacted 100% with the metabolites these data suggest that the concentrations of the hexa-and pentapeptide in normal venous blood were small. Results are expressed as mean ± SD where four or more experiments (numbers in parentheses) were performed. One peptide was added to each 20-ml blood sample. Results are expressed as pmol/liter of plasma or pmol/liter of blood; ± represents I standard error. • Samples drawn simultaneously with arterial blood. bated at room temperature for up to 5 hours are shown in Table 4 . Plasma levels of A II IM remained constant despite a progressive increase in the concentration of A I. Interference from A I would therefore appear to be negligible. In the remaining experiments, A I and A II were assayed in four normal venous plasma extracts after chromatog- raphy in solvent system A. The mean ratio of A I to A II was 13:1 (range, 9:1-17:1), indicating that only about 8% of the A II could be accounted for by A I, taking into account the cross-reaction of the A II antiserum with A I.
CONTRIBUTION OF A I TO APPARENT A II The plasma concentrations of A I and A II IM in samples of normal venous blood containing inhibitor solution incu-
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CATABOL1SM OF A II AND ITS METABOLITES IN BLOOD
Half-lives for A II, the heptapeptide, hexapeptide, and pentapeptide were 4.4, 2.0, 1.9, and 2.4 minutes, respectively ( Fig. 6 ). 'l "alue for the hexapeptide may be an underestimate bee;, se conversion of hexa-to pentapeptide will not be accounted for. The delay between withdrawing blood from a subject and its mixing with inhibitor was never more than 30 seconds, and thus the peptide pattern was not likely to alter significantly during this period.
This was corroborated by comparing the pattern of A II and its metabolites in three samples of normal venous blood drawn into syringes containing inhibitor solution with the pattern obtained when blood was mixed with inhibitor in a container after sampling. No differences could be determined. A mean of 76% of the A II IM chromatographed with the mobility of A II in both groups.
EFFECT OF DELAY IN ADDING INHIBITOR SOLUTION
These results are summarized in Table 5 . Incubation of blood without anticoagulant and without inhibitor solution for 10 minutes resulted in an 80% increase in the concentration of A II but no significant change in the proportions of the various peptide metabolites. In the heparinized samples a progressive rise in A II concentrations was also apparent but again there was no change in the proportion of metabolites. The rise in A II concentration was smaller in the hemolyzed sample, probably because of liberation of red cell angiotensinases. Results are expressed as pmol/hter of plasma or pmol/litcr of blood; ± represents I SE.
• Sample drawn simultaneously with arterial blood.
Discussion
The results of the present study differ substantially from those reported in preliminary forms by Cain et. * "" These workers found that only some 28% of A II immunoreactive material in venous blood is A II, the bulk of such material being in their view the 3-8 hexapeptide metabolite. We have found, by contrast, that 55-100% of such immunoreactive material is A II in venous, as in arterial, plasma and have 21 Several possible explanations for the discrepancy between our findings and the earlier work have been considered.
A contribution of A I to the apparent A II content was excluded by specific measurements of both peptides and the relationship of these to the cross-reactivity of the A II antiserum with A I.
When the effect of deliberate delay in inhibiting blood converting enzyme and angiotensinases was studied, it was found that there was an increase in the concentration of A II but that the relative proportion of metabolites were little changed. Thus it seems unlikely that changes occurring after blood sampling could explain the differences between the studies, particularly when we routinely accomplished angiotensinase inhibition rapidly in relation to the rates of breakdown of the peptides studied. The concentrations which we found are probably close to those prevailing in vivo.
It may be that the A II antiserum we used had different affinities for the peptide metabolites from that of the previous workers. Cain et al.*' " and Catt et al. J1 did not provide details of the affinity of their antiserum for the three metabolites. In a separate study the same group referred to an A II antiserum which had a slightly higher affinity for the 3-8 hexapeptide than for A II at low concentrations of peptide," although the cross-reaction of this particular antiserum with the 4-8 pentapeptide was not documented. A particularly high affinity of an A II antiserum for peptide metabolites, such as the 4-8 pentapeptide, would result in a falsely high estimate of its concentration in blood. Emanuel et al." have described an A II antiserum with a disproportionately high affinity (15-to 40-fold) for the 3-8 hexapeptide. Using this antiserum, these workers found similar venous and arterial concentrations of A II immunoreactive materials, a finding which led them to query the results of Cain et al.' Our observations with an antiserum having a low affinity for the hexa-and pentapeptide complement those of Emanuel et al." and corroborate our chromatographic findings.
The arteriovenous difference in endogenous plasma A II concentrations across the limb was small (14%) ( Table 2) . This contrasts with observations that exogenous A II, in amounts above the physiological range, loses 50-60% of its biological activity in one circulation through the limb vasculature of animals. 84 " 17 Studies on the fate of A I in animals have led to the recognition of the lung as the principal site of angiotensin conversion." The situation in man is less clearly defined. Estimates of the degree of pulmonary conversion with the systemic pressor response technique range from 0% to 40%,""" which suggests that there may be appreciable conversion in peripheral tissues." Conversion of injected A I has been demonstrated in the limb vessels of normal man, 12 and subjects on cardiopulmonary bypass have appreciable circulating levels of A II.' 1 During intravenous infusion of A II the arteriovenous gradient in plasma levels of A II IM increases with the infusion rate. 14 These observations suggest that A II is both generated and destroyed in the limb vessels and this may explain our finding of a modest difference between arterial and venous plasma levels of the hormone.
Since the bulk of A II immunoreactive material in arterial and venous blood is authentic A II, it seems unnecessary to include a procedure which separates A II from its immunoreactive metabolites in routine immunoassay methods for measuring the hormone in human blood.
